| Company Name | Announcement |
|---|---|
| Sammaan Capital
Sammaan Capital
[15-Oct-2026] |
Sammaan Capital Limited reported that it has made timely payments of interest amounting to Rs 1860.00 lacs for its secured redeemable non-convertible debentures with ISIN INE148I07YE1 and Rs 1830.00 lacs for debentures with ISIN INE148I07YF8, both issued on a private placement basis and listed on the National Stock Exchange of India Limited and BSE Limited, with due dates of October 16, 2026, and payments made on October 15, 2026.</p> |
| SIS
SIS
[15-Oct-2026] |
SIS Limited announced it bought back 3,000 equity shares through BSE and 28,000 equity shares through NSE on October 15, 2026, as part of its ongoing buyback program, bringing the total number of shares repurchased to 24,91,968. The average acquisition price was Rs 407.4935 per share, excluding transaction costs, according to a regulatory filing.</p> |
| Eros Intl.Media
Eros Intl.Media
[15-Oct-2026] |
EROS International Media Limited informed the BSE Limited and National Stock Exchange of India Limited that it received a certificate from MUFG Intime India Private Limited, formerly Link Intime India Private Limited, under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.</p> |
| Mankind Pharma
Mankind Pharma
[15-Oct-2026] |
Mankind Pharma announced it will acquire a 70% stake in Belgium-incorporated biotechnology company Armed Cell Therapeutics B.V. (ACTx) through its Netherlands subsidiary, Mankind Pharma (Netherlands) B.V., for a consideration of EUR 48 million. The acquisition, part of Mankind Pharma’s strategy to build a global innovation-led pharmaceutical business, will be funded through an additional investment of up to EUR 45 million in Mankind Pharma (Netherlands) B.V., bringing the total investment to EUR 50 million. ACTx is developing next-generation chimeric antigen receptor T-cell (CAR-T) therapies for cancer, with lead programs targeting non-Hodgkin lymphoma and small cell lung cancer.</p> |
| Mittal Sections
Mittal Sections
[15-Oct-2026] |
Mittal Sections Limited submitted a certificate to the BSE Limited issued by Bigshare Services Private Limited, confirming compliance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026. Bigshare Services Private Limited also confirmed that the aforementioned regulation is not applicable to the company as all shares are held in demat form and no requests for rematerialization or dematerialization were received during the same period.</p> |
| Asian Hotels (W)
Asian Hotels (W)
[15-Oct-2026] |
Asian Hotels (West) Limited submitted a compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as confirmed by KFin Technologies Limited, the company’s Registrar and Share Transfer Agent.</p> |
| Future Market
Future Market
[15-Oct-2026] |
Future Market Networks Limited submitted a certificate to the National Stock Exchange of India Limited and BSE Limited under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026, as received from MUFG Intime India Private Limited, formerly known as Link Intime India Private Limited, its Registrar and Share Transfer Agent.</p> |
| Aditya Birla Cap
Aditya Birla Cap
[15-Oct-2026] |
Aditya Birla Capital Limited announced the allotment of 40,000 secured, rated, listed, taxable, and redeemable non-convertible debentures to identified investors on October 15, 2026, with a total issue size of Rs 400 crore, aggregating to Rs 4,00,00,00,000. The debentures will be listed on the BSE Limited and National Stock Exchange of India Limited and have a tenor of 701 days, with a coupon rate and redemption date of September 15, 2028.</p> |
| Dodla Dairy
Dodla Dairy
[15-Oct-2026] |
Dodla Dairy Limited will hold a board meeting on Wednesday, October 28, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026, along with the Limited Review Report(s) of the Statutory Auditor. The company’s trading window for designated persons and their immediate relatives will remain closed until 48 hours after the declaration of the financial results.</p> |
| Health.Global
Health.Global
[15-Oct-2026] |
HealthCare Global Enterprises Limited informed the National Stock Exchange of India Limited and BSE Limited that it has furnished details of securities dematerialized and/or rematerialized during the quarter ended September 30, 2026, pursuant to Regulation 74(5) of Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, and enclosed a certificate from Kfin Technologies Limited, its Registrar to Issue and Share Transfer Agent, dated October 15, 2026.</p> |
Old Backoffice
Data available till FY 2024-25 (Historical)
New Backoffice
Data From FY 2025-26 onwards (Latest)
